Phase 2 Study of the Efficacy and Safety of Venetoclax in Combination With Ibrutinib in Japanese Subjects With Relapsed/Refractory Mantle Cell Lymphoma
Latest Information Update: 19 Mar 2024
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors AbbVie
- 12 Mar 2024 Planned primary completion date changed from 14 Feb 2022 to 4 Oct 2025.
- 18 Dec 2023 Planned End Date changed from 12 Dec 2023 to 30 Jun 2025.
- 21 Dec 2022 Planned End Date changed from 22 May 2023 to 12 Dec 2023.